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Introduction
A diagnosis of diabetes will naturally impact an individual’s life.
Unfortunately, the type of diabetes is rarely conﬁrmed, and patients
and their physicians rarely question the classiﬁcation. Some data
show that 7% to 15% of patients are incorrectly classiﬁed (1). This
challenge of diagnosis is especially relevant in young adults in whom
the risk for error increases, particularly soon after diagnosis. Most
cases of diabetes among people aged 15 to 40 years are type 1, while
a minority are type 2, although type 2 is on the rise in this demo-
graphic due to the obesity epidemic, particularly among ethnic
minorities (2). Atypical forms also appear at this age (2). Table 1
and Table 2 outline the clinical features that call into question a diag-
nosis of type 1 diabetes and highlight the possible overlapping fea-
tures of monogenic diabetes and type 2 diabetes. This article focuses
on monogenic diabetes and neonatal diabetes. Maternally inher-
ited diabetes and deafness (MIDD) have been reviewed elsewhere
(Table 3) (3–5).
Clinical cases with features atypical for type 1 and type 2 diabetes
A young, lean patient with a multigenerational family history
of diabetes
A 29-year-old woman is referred for atypical diabetes. Following
an episode of hyperthyroidism, she was diagnosed with diabetes at
age 24 despite a body mass index (BMI) of 19 kg/m2. At the time of
diagnosis, she showed high postprandial glucose levels but normal
fasting glucose levels. She did not toleratemetformin, so shewas on
a diet alone for the next 4 years and her glycated hemoglobin (A1C)
levels rose from 6.0% to 7.4%. Her oral glucose tolerance test (OGTT)
showed an increase in glucose levels from 8mmol/L to 18mmol/L
at2hours.NonfastingC-peptide levelswere526 pmol/L (normal>200)
andhigh-sensitivityC-reactiveprotein (hsCRP)werebelowthe thresh-
old of detection (<0.17mg/L). Her lipid proﬁle showed triglycerides
of 1.96 mmol/L, high-density lipoprotein (HDL)-cholesterol of
2.19 mmol/L and low-density lipoprotein (LDL)-cholesterol of
2.19mmol/L. Her mother was diagnosed at age 29 following preg-
nancy and has been controlled with glyburide since that time. The
sister of the patient was also diagnosed with diabetes at age 29 but
has had glycosuria since age 18. Her glycemic control has deterio-
ratedwhile onanappropriate diet,withA1C levels at 8.2%. Themater-
nal grandfather also had diabetes.
Pregnant patient with persistent mild fasting hyperglycemia
A 30-year-old patient who is in the second trimester of her third
pregnancy was followed by her endocrinologist. Insulin was started
at week 8 due to elevated fasting plasma glucose (6 mmol/L). This
scenario is similar to that of both of her previous pregnancies, which
resulted inmacrosomic newborns. Outside of pregnancy, the patient
presented with slightly elevated fasting plasma glucose (FPG) levels,
a BMI of 21 kg/m2 and A1C levels of 6.0%. Her father showed
impaired fasting glucose, untreated since young adulthood, and her
mother showed impaired glucose tolerance and hypertension.
Patient claiming she was born with diabetes
A 46-year-old patient was diagnosedwith diabetes at the age of
2 months. She was taking insulin irregularly over this long period
of time, with diﬃcult control on oral agents alone but without ever
developing ketoacidosis. She was currently poorly controlled on
gliclazide, saxagliptin and insulin glargine, with usual A1C levels
>8.5%. C-peptide levels were variable over time (between 30 and
385 pmol/L), and pancreatic autoantibodies were negative. Inten-
sive insulin therapy was not possible due to a psychiatric disease.
Her 70-year-old mother was also diagnosed with diabetes and on
metformin therapy, andher daughter hadhaddiet-controlled hyper-
glycemia since the age of 15.
Monogenic diabetes (maturity-onset diabetes of the young [MODY]):
General information
Monogenic diabetes is a heterogeneous disease resulting from
themutation of a single gene with an important role in the beta-cell
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signalling function or growth or insulin transcription (6,7). This form
of diabetes is usually inherited in an autosomal dominant pattern
(statistically, by 50% of offspring) and more rarely through spon-
taneous mutations (8). To date, at least 13 genes have been iden-
tiﬁed (2,9). Busy clinicians may be baﬄed by the sheer complexity
of the genes, but the information gathered would not be useful in
identifying the vast majority of cases; 90% of nonsyndromic forms
are attributed to 3 genes (Figure 1) (10). Mutations in MODY genes
show very high penetrance for developing diabetes. Diagnosis usually
occurs early in life, during childhood, adolescence or early adult-
hood. More than 80% of cases of MODY are not diagnosed, and it
often takes more than 10 years before a diagnosis is made (10). The
best estimates of prevalence suggest that 1% to 2% of all cases of
diabetes are actually monogenic forms (10–13). This means that just
under 1% of presumed cases of type 1 diabetes and 4% to 5% of of
cases of adults diagnosed with type 2 diabetes before the age of
45 are actually monogenic forms of diabetes (12). In Americans
younger than 20 years of age, close to 10% of diabetes cases in the
presence of residual insulin secretion and the absence of pancre-
atic autoantibodies are actually cases of monogenic diabetes (13).
Hepatocyte nuclear factor (HNF1A and HNF4A) monogenic diabetes
HNF1A-MODY (MODY 3) is the most common form of mono-
genic diabetes in most studies, representing at least 50% of cases
(7,10,12,13). Approximately 60% of carriers develop diabetes by age
25, 80% by age 35 and 95% by age 55 (6,14). Mutation of the HNF4A
Table 1
When to suspect a diagnosis of type 1 diabetes (T1D) may not be correct (12,19,81–88)
Clinical feature Type 1 diabetes Monogenic diabetes
Family history of diabetes 19% with parental history of diabetes*
<10% with parental history of T1D
0–2% of T1D with 3 generations of T1D
90%**, multigenerational
Absence of islet cell autoantibodies, particularly if measured at the
time of diagnosis***
15–40%, depends on method and number of antibody tested 99%
Evidence of endogenous insulin secretion 3–5 years after diagnosis
(C-peptide measurement)
Rare (<10% of T1D) Yes
Absence of autoantibodies and presence of family history of diabetes <5% Usually
* From reference (19).
** Consider variable accuracy of family history report and the possibility of spontaneous mutations.
*** Consider the possibility of negative autoantibodies with longer duration of T1D.
Table 2
Overlapping clinical features of monogenic diabetes and type 2 diabetes (12,13,19,23,89–91)
Clinical feature Early-onset type 2 diabetes Monogenic diabetes
Family history of diabetes 61%, often both parents 90%, multigenerational
Absence of islet cell autoantibodies ±90%a 99%
Evidence of endogenous insulin secretion 3–5 years after diagnosis The majority Yes
Obese, metabolic syndromeb or acanthosis nigricans The majority Rare (characteristics of the general population of the same age)
Lipid proﬁlec
Triglycerides 1.49 mmol/L 1.16 mmol/L
HDL-cholesterol 1.06 mmol/L 1.46 mmol/L
Fasting triglycerides<1.8 mmol/L and normotensived 24% 78%
a Consider the prevalence of latent autoimmune diabetes of the adult (LADA) in some cases of presumed type 2 diabetes.
b The best deﬁnition of metabolic syndrome is controversial, especially in children.
c Based on one study of HNF1A-MODY (average age 38 years old, average age at diagnosis 19 years old) compared to type 2 diabetes (average age 65 years old, average
age at diagnosis 50 years old). These results may not be representative of all population groups (23).
d These results may not be representative of all population groups (91).
Table 3
Key features of maternally inherited diabetes and deafness (MIDD) (3–5)
Maternally inherited diabetes and deafness
Mutation 3243A>G mitochondrial point mutation
Transmission Mitochondrial: From mother to child
Men have the disease but cannot pass it on to their
children
Pathophysiology Breakdown in mitochondrial cellular respiration
leading to beta-cell dysfunction
Clinical presentation Insidious like type 2 diabetes, acute like type 1
diabetes (20%); diabetic ketoacidosis<10%
Mean age 37±11 years of age (80% before 70 years of age)
Peak 25–40 years of age
Prevalence Mean 0.8% for European descendants with diabetes
5% if deafness or family history of deafness on
maternal side
Other features Neurosensorial deafness (>75%), short stature,
pigmentary maculopathy (>85%), neurologic
syndrome and myopathy (40%), nephropathy and
proteinuria, heart failure, etc.
Variable familial phenotype dependent on
heteroplasmy level
Treatment Avoid metformin and statin (myopathy risk)
Insulin usually required eventually
MODY 
HNF1A 
52% 
(MODY 3) 
Glucokinase 
(GCK) 32% 
(MODY 2) 
HNF4A 
10% 
(MODY 1) HNF1B (renal 
cysts and diabetes) 
6% 
(MODY 5) 
INS/NeuroD1 
• <1% 
Macrosomia≈50% 
Neonatal 
hypoglycemia≈15% 
Figure 1. Distribution of monogenic diabetes (10,15).
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gene (MODY 1), which is diﬃcult to differentiate clinically except
formacrosomia and prolonged neonatal hypoglycemia, accounts for
approximately 10% of cases (10,15,16). HNF genes play key roles in
insulin signalling in beta cells, and an HNF gene mutation greatly
affects the insulin secretory response to elevated intracellular glucose
levels (7). A loss of the incretin effect and abnormalities in gluca-
gon are also described (17). The disease is generally characterized
by near-normal fasting glucose levels (mean 6.0 mmol/L) and abnor-
malpostprandial levels (mean2-hourplasmaglucoseof 11.2mmol/L)
in youngadulthood (18).However, fastingplasmaglucose (FPG) levels
continue to increase over time, and the features of the disease may
exhibit overlap with poorly controlled type 1 and type 2 diabetes
(19,20). Hence, A1C levels vary greatly from one patient to another
(19). In 2 studies, the risks formicrovascular andmacrovascular com-
plications related tohyperglycemia inHNF-MODYappeared to remain
similar over time to those of type 1 and type 2 diabetes, although
the lipid proﬁle may be falsely reassuring for the evaluation of car-
diovascular disease risk (Table 2) (21–23).
Treatment of HNF1A and HNF4A monogenic diabetes
Despite the lack of evidence-based data concerning treatment
of hyperglycemia and vascular risk factors, rigorous management
of the disease is necessary, considering the risk for complications.
Application of the recommendations for managing type 1 diabetes
(lipids, blood pressure) may be appropriate (21). Sulfonylureas are
a perfect example of a pharmacogenetic response by patients with
HNF1A-MODY and HNF4A-MODY and are considered the treat-
ment of choice. A classic study demonstrates a 5 times greater reduc-
tion in FPG levels in response to gliclazide than to metformin in
patients with HNF1A-MODY. Closing adenosine triphosphate (ATP)-
sensitive potassium channels, the drug appears to act down-
stream of the cellular defect caused by themutation (7,24). Clinicians
should typically start treatment at an ultralow dosage (25% to 50%
of the normal starting dosage), considering the risks for hypogly-
cemia associated with the higher dosages usually administered to
patients with type 2 diabetes. As the diabetes progresses over time,
sulfonylurea sensitivity decreases, and more intensive treatment is
often required, eventually insulin (25). Most insulin-treated patients
who have never taken oral agents are able to simplify their drug
regimen on sulfonylureas or even discontinue insulin therapy (25).
Genetic testing can certainly bring life-changing diagnoses to these
patients usually considered to have type 1 diabetes (Table 1).
More recently, nateglinide has been shown to be effective, with
signiﬁcantly lower incidences of hypoglycemia than glyburide (26).
A recent study comparing a glucagon-like peptide-1 (GLP-1) agonist
with glimepiride demonstrated equivalent eﬃcacy for both agents
and 10 times less hypoglycemia with liraglutide (27). Case reports
suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors also dem-
onstrate eﬃcacy (28). On the physiologic front, sodium-glucose
cotransporter type 2 (SGLT2) inhibitors should be avoided due to
the already decreased renal threshold for glucose in patients with
the HNF1A mutation, which could lead to more dehydration and
genital infection (29,30). Clearly, more data are needed to evaluate
the eﬃcacy and safety of this class of drug in this form of diabetes.
Implications and treatment of HNF-MODY in pregnancy. Although
these mutations can certainly be present in pregnancy (1% or less
of gestational diabetes cases), the best strategy to identify them is
still unknown at the moment (31–33). Until better data are avail-
able, reliance on practice guidelines for MODY may be appropri-
ate (Table 4) (34). HNF1A-mutation carrier newborn did not have
a higher incidence of macrosomia compared to nonmutated fetus
in 2 studies, with maternal hyperglycemia easily managed with
current insulin protocols (15,35). Exposure to hyperglycemia in utero
(from the mutation-carrying mother) led to diabetes appearance
5 to 12 years earlier in life and insulin treatment starting sooner
compared to inheriting the mutation from the father (14,36).
By comparison to HNF1A-MODY, an HNF4A-mutation carrier
newbornhada56%chanceofmacrosomia (meanbirthweight4450 g)
and a 15% chance of prolonged neonatal hyperinsulinemic hypogly-
cemia,with amedian glucose level of 1mmol/L. Inmost cases, intra-
venous glucose and enteral feeding were needed (15). Macrosomic
infants with prolonged hyperinsulinemic neonatal hypoglycemia
shouldbe screened for theHNF-4Agenemutation, particularly if there
is a family history of youth-onset diabetes (15,31). Serial antenatal
fetal ultrasound should be performed with considerations for early
delivery in the presence of macrosomia. All offspring of pregnancies
in which the father or mother is an HNF4A-mutation carrier should
be tested for hypoglycemia at birth and 24 hours later (15).
Treatment of maternal hyperglycemia for HNF1A- and HNF4A-
MODY is indicated according to best-practice guidelines for gesta-
tional diabetes (35,37). Insulin and maybe glyburide, depending on
the country-speciﬁc guideline for its use in pregnancy, should be
used to reach glycemic targets (37).
HNF1B-MODY. HNF1B gene mutation (MODY5) is associated with
genitourinarymalformations, renal cysts, renal failure, hypomagne-
semia, early gout, pancreatic atrophy and exocrine pancreatic failure
in addition to diabetes (38). Diabetes will usually be diagnosed after
diagnosis of the renal disease (38). Although theyare lean (meanBMIs
of 27 in1 study), patients presentwithmorephysiologic insulin resis-
tance than in thosewithHNF1A-MODY (39). They also have lowbeta
cell mass and do not respond particularly well to sulfonylureas (39).
Insulin is usually indicatedwithprogressionof diabetes in these cases.
Glucokinase (GCK) monogenic diabetes
Glucokinase (GCK)-MODY (MODY 2)—themost common form of
MODY in certain populations, such as those in France and Italy—
presents as mild asymptomatic fasting hyperglycemia that is often
detected incidentally, especially in pediatric populations (40–45).
Studies suggest a population prevalence of 1 of 1000 to 1 of 2000,
includingQuébec-based data (45–47). Glucokinase is a key glycolytic
enzyme for facilitating phosphorylation of glucose to
glucose-6-phosphate (the ﬁrst rate-limiting step in glucose
metabolism) and for regulating glucose levels (pancreatic glucose
sensor) (7). In the presence of inactivating mutation, insulin secre-
tion is reset at higher glycemic levels, and suppression of hepatic glu-
coneogenesis is reduced(42,45).Patientswiththesemutations typically
have slightly elevated FPG levels (5.5 to 8mmol/L) from birth and
Table 4
European best practice guidelines supporting a diagnosis of transcription factor (HNF) monogenic diabetes (34)
Young-onset diabetes (typically before 25 years of age in at least one family member)
Non-insulin dependant outside the normal honeymoon period (no ketoacidosis in the absence of insulin, good glycemic control on less than the usual replacement
dose of insulin, or detectable C-peptide measured when on insulin)
Family history of diabetes (at least two generations); may be insulin treated and considered to be type 1 diabetes or type 2 diabetes at least two individuals within the
family diagnosed in their 20s or 30s; if there’s an affected grandparent, often diagnosed after age 45
Absence of pancreatic islet autoantibodies
Glycosuria at lower than usual blood glucose levels
Marked sensitivity to sulfonylureas
Features suggesting monogenic diabetes: No marked obesity or evidence of insulin resistance, an ethnic background with a low prevalence of type 2 diabetes (e.g. of
European descent)
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only a small increase in postprandial glycemia (18,20,45,48). TheA1C
levels observed in a large UK series were 5.6% to 7.3% before age 40
and 5.9% to 7.6% after age 40 (48). However, double diabetes (with
obesity, insulin resistance and GCK-MODY) outside of these ranges
has beendescribed (45,49). Inmost cases, a valuebelow these thresh-
oldsora fastingbloodglucosebelow5.4mmol/Lexcludes thisdiagnosis
(48). Given that GCK-MODY presents as a mild form of hyperglyce-
mia, the gene-carrier parentmay not be diagnosed as being diabetic.
GCK-MODY and pregnancy. Given today’s universal screening rec-
ommendations, pregnancyoffers auniqueopportunity for diagnosing
GCK-MODY. In fact, all pregnant carriers of the genemutation have
fasting blood glucose levels above the diagnostic threshold for
gestational diabetes in Canada (37). The fetuswill have a 50% chance
of inheriting the mutation. Some authors have recently suggested
that approximately 0.5% to 3% of cases of gestational diabetes are,
in fact, GCK-MODY (47,50–52). Certain criteria, such as normal
prepregnancyBMI (<25 kg/m2), fastingglucoseorOGTTcriteria, family
history and the need for insulin only during pregnancy, with sub-
sequent control on diet, may help to identify these cases better,
whereas the A1C thresholds discussed earlier are probably not reli-
able (Tables 5, 6) (47,51,52). Recently, 1 group showed higher fasting
and postprandial glycemic excursions, particularly in the ﬁrst tri-
mester,withGCK-MODY compared toHNF1A-MODY, despite insulin
treatment (35). A higher proportion of miscarriages was observed
in the GCK groupwhen compared to the HNF1A-MODY group (35).
The implications of hyperglycemia during pregnancy are out-
lined in Figure 2 and have been reviewed recently (45). The best pre-
dictor of fetal weight is, in fact, the baby’s own genotype and not the
treatment used to managematernal hyperglycemia (diet or insulin)
(35,45,53).When there is discordancebetween thematernal and fetal
genotypes such that the fetus does not carry the mutation, treat-
ment is initiated in order to prevent macrosomia. In the absence of
fetal genotyping, theuseof serialultrasounds (tomonitor fetal abdomi-
nal circumference)beginningat26weeksof gestationoramniocentesis
(only if already indicated for other conditions) may prompt the
administration of insulin in cases of genotype discordance between
the affected mother and her fetus or when there is ultrasound evi-
dence of increased fetal abdominal circumference >75th percentile
(45,53–57). This strategy requires validation in a future study.
Treatment of GCK-MODY. Patients with GCK-MODY have very low
risks for complications over the course of a lifetime (similar to those
of the nondiabetic population over a period of 50 years), which
supports the concept of well-regulated mild hyperglycemia in these
patients (58). The eﬃcacy of common antidiabetes drugs has not
been demonstrated, and lifestyle modiﬁcation is the only treat-
ment recommended for these patients (59). The usual monitoring
Table 5
European best practice guidelines supporting a diagnosis of GCK-MODY (34)
Mild fasting hyperglycemia of ≥5.5 mmol/L (98% of patients), persistent (at least three separate occasions) and stable over a period of months or years, or during
pregnancy
HbA1c is typically just above the upper limit of normal and rarely exceeds 7.5%
In an oral glucose tolerance test (OGTT) the increment is small, typically <4.6 mmol/L (71%<3 mmol/L)
Parents may have type 2 diabetes with no complications or may not have diabetes. On testing, one parent will usually have mildly raised fasting blood glucose
During pregnancy, the absence of family history should not exclude the diagnosis
Table 6
GCK-MODY useful clinical diagnostic combinations in pregnancy: FPG (oral glucose
tolerance test (OGTT) at 24 to 28 weeks) and prepregnant BMI (47)a
Clinical criteria Number needed to
test for a positive
GCK genetic test
Percentage of cases
of GCK-MODY
identiﬁed
FPG≥5.5 mmol/l and BMI<30 6.5 82%
FPG≥5.5 mmol/l and BMI<25 2.7 68%
FPG≥5.5 mmol/l and BMI≤21 1 20%
Deciding on the best cut-off values will depend on the results of cost/beneﬁts appraisal
when testing patients for the mutation. A fasting plasma glucose (FPG) ≥ 5.5 mmol/l
and a body mass index (BMI) < 25 can be considered appropriate cut-off values at
the moment in most cases.
a Data from the population-based Atlantic Diabetes in Pregnancy study.
Mother GCK+
Fetus GCK+
Similar glucose sensing
Low risk of macrosomia without treatment
Risk of intrauterine growth retardation if 
maternal hyperglycemia overtreated
Mother GCK+
Fetus GCK-
Discordant glucose sensing
Macrosomia risk multiplied by 6 without 
treatment
Mean birthweight increased by 700 g
Mother GCK-
Fetus GCK+ 
(mutation inherited from the father)
Discordant glucose sensing
Mean birthweight decreased by 500 g
Mother GCK-
Fetus GCK-
Usual approach in pregnancy
GCK-MODY
Figure 2. Birth weight based on genotype concordance with glucokinase mutation carrier status of mother (35,45,53,55,92–94).
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of complications associated with hyperglycemia may not need to
be as intensive as in diabetes and may not be required at all (58).
Neonatal diabetes
Very rare (an incidence of fewer than one in 100,000 live births),
neonatal diabetes is usually deﬁned as the appearance of diabetes in
the ﬁrst 6months of life, a period duringwhich presentation of auto-
immune diabetes is very rare (60–65). Molecular genetic diagnosis
is nowpossible for 80%of cases during this period and shouldbedone
without delay (Table 7) (60,65). Between 6 and 12 months of age,
althoughneonatal diabetes is still possible, type1diabetes is farmore
prevalent (60,62). Neonatal diabetes can be transient, which means
it will resolve after several months of life, but it may later relapse
during adolescence or may be permanent. The detection of activat-
ing mutations in the potassium inward rectiﬁer 6.2 subunit (Kir6.2)
and sulfonylurea-receptor subunits (SUR1) of the beta-cell ATP-
sensitive potassium channel was a revolutionary advance (66–68).
Thesemutations affect about 40% of patientswith neonatal diabetes
andmay respondmuchbetter to highdoses of sulfonylureas (median
dose of 0.5mg/kg of glyburide) than to insulin, allowing insulin treat-
ment to be discontinued in approximately 90% of affected children
(69). The drug causes the ATP-sensitive potassium channels to close
and ultimately triggers insulin secretion (69). This form of diabetes
is sometimes associated with neurodevelopmental abnormalities
(DEND syndrome) that may also respond well to sulfonylurea (70).
Considerations for selection of patients for genetic testing
European guidelines were published in 2008 to better orient
genetic screening of patients (Tables 4, 5) (34). Positive test preva-
lence is usually 20% to 40% and appears to vary little among the
various regions of the United Kingdom, whereas there is consid-
erable variation in referral rates (10). Next-generation sequencing
allows for multiple genes to be investigated in a single test, result-
ing in diagnosis in approximately 15% to 30% of patientswith disease
undetected by traditional methods (71,72). Although this is con-
troversial, 1 study shows that screening for MODY may be cost-
effective if the pretest probability is greater than 25% to 30%, possibly
lower in insulin-treated patients (73,74). In 1 societal cost-utility
analysis comparing a policy of routine genetic testing compared to
no testing among childrenwithpermanent neonatal diabetes, testing
produced savings in total costs thatwere present as early as 10 years
of follow up (75). Although the cost of genetic testing, which has
beendecreasing in thepast decade,mayappear to be a limiting factor,
the tremendous impacts over the long term of less expensive and
more effective treatments, the cessation of insulin for many cases
and the more appropriate monitoring of patients and their fami-
lies (plasma glucose tests, blood tests, complications, etc.) must be
taken into consideration (Table 8) (76).
Individual clinical features may help to differentiate type 1 and
type 2 diabetes fromMODY (Tables 1, 2). In 1 study, the main char-
acteristics that suggested MODY rather than type 1 diabetes were
parental histories of diabetes, older ages at diagnosis and lower A1C
levels (19). The characteristics that suggested MODY rather than
type 2 diabetes in the same study were lower BMIs, younger ages
at diagnoses, lower A1C levels, parental histories of diabetes and
not being treated by oral agents or insulin (19). A MODY probabil-
ity calculator, recently also available in the Diabetes Diagnostics
application, was designed and developed by the renowned team
at Exeter in the United Kingdom (MODY probability calculator;
www.diabetesgenes.org/content/mody-probability-calculator). This
calculator can be used in patients diagnosed with diabetes before
age 35 to calculate the probability of MODY, identifying which
patients should be tested by answering 8 simple questions (19,73).
The inclusion of biochemical features can further increase the cal-
culator’s robustness and accuracy (77). However, we do not yet know
the best strategy for identifying monogenic diabetes among ethnic
minorities because the prevalence of type 2 diabetes and the overlap
of clinical characteristics may be higher (78). In addition, given that
the C-reactive protein gene has an HNF1A binding site in its pro-
moter, hsCRP is typically low (less than 0.75 mg/L) in patients with
the HNF1A mutation, providing good discrimination between
HNF1A-MODY and type 2 diabetes (79,80). Figure 3 and Figure 4
are algorithms that integrate simple clinical features and afford-
able tests at the outset that can be used in clinical practice to dis-
tinguishMODY from early-onset type 1 diabetes and type 2 diabetes.
Genetic counselling is appropriate for asymptomatic family
members requestingpredictive testing. A simple biochemical test can
be offered ﬁrst (A1C, OGTT, FPG), and should the result suggests the
presence of themutation, it can be followedwith genetic testing (34).
For children too young to give informed consent, referral to a clinical
genetics unit is recommended. Good reasons for testing for HNF1A-
MODY and HNF4A-MODY would be to resolve uncertainty about a
child’s statusandtostopperiodicbiochemical testing followup,usually
beginning at an early age, if the mutation is negative (34).
Solutions to the Clinical Cases
The ﬁrst patient had a very high probability of having MODY
according to the MODY probability calculator (>75%) and tested
positive for HNF1A-MODY (c. 375 to 377 dup). Her sister also tested
positive for the same mutation. The 3-generation family history of
diabetes, the normal C-peptide level 5 years after diagnosis, the very
low hsCRP levels and low BMIs were useful clues to the diagnosis.
The sisters are on low dosages of repaglinide and gliclazide, respec-
tively, and have achieved better control.
Table 7
Simpliﬁed distribution of neonatal diabetes (60,62–65)
Neonatal diabetes Genes Approximate
gene prevalence
Permanent≈45% Kir.6.2 (KCNJ11)
SUR1 (ABCC8)
Insulin
GCK (homozygous or compound
heterozygous)
Unknown
31%
10%
12%
2–3%
Transient≈45% 6q24
Kir6.2 (KCNJ11) and SUR1 (ABCC8)
70%
25%
Syndromes and
pancreatic
aplasia≈10%
EIF2AK3 (Wolcott-Rallison)
FOXP3 (IPEX syndrome)a
GATA6, GATA4, NeuroD1, IPF-1, etc.
—
a IPEX syndrome: immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome.
Table 8
Non-exhaustive list of laboratories offering genetic testing with approximate cost
in Canadian dollars (98–103)a
Laboratories
(in alphabetical order)
Athena Diagnostics, Marlborough,
Massachusetts, USA
Centogene, Germany
CGC Genetics, Newark, New Jersey, USA
Chicago University, Chicago, Illinois, USA
Exeter Clinical Laboratory, United Kingdom
Seattle’s Children Hospital, Seattle,
Washington, USA
Approximate cost for HNF or
glucokinase mutation testing
$830–$2700
Approximate cost for sequencing
a known familial mutation
$240–$570
Approximate cost for full gene or
next generation sequencing
panel for MODY
$1950–$7800
a Cost may vary from one institution to another.
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* This algorithm is intended as a clinical tool and should not replace expert clinical 
judgement. The MODY probability calculator is also very useful in identifying which 
patients should be tested.
**Although possible in MODY, diabetic ketoacidosis is rare compared to T1D.
***Islet cell autoantibodies should be tested soon after diagnosis to improve sensitivity.
****HNF4A is found in about 30% of patients testing negative for HNF1A.
Test HNF1A then HNF4A if negative****
If negative, consider next generation sequencing
GAD/IA-2A/ICA/ZnT8 antibodies negative (ideally in combination)***
Fasting C-peptide>80 pmol/l or random C-peptide>200 pmol/l 3-5 
years after diagnosis or for the parent with long duration diabetes 
Parental history of diabetes
Presumed type 1 diabetes diagnosed before 35 years old
No history of diabetic ketoacidosis**
Figure 3. Proposed diagnostic approach for differentiating transcription factor (HNF) monogenic diabetes from type 1 diabetes (T1D) (2,12,16,71,72,77,86–88,95,96).
* This algorithm is intended as a clinical tool and should not replace expert clinical 
judgment. The MODY probability calculator is also very useful in identifying which patients 
should be tested.
** hsCRP will typically be below this threshold for HNF1A-MODY but not HNF4A 
hsCRP should be tested outside of acute inflammation.
***HNF4A will be found in about 30% of patients testing negative for HNF1A.
Test HNF1A mutation then HNF4A if negative***
If negative, consider next generation sequencing 
hsCRP very low, often close to the laboratory's detection limit 
(typically<0,5-0,75 mg/l)**
Age at diagnosis<25-30 with parental history of diabetes and/or 
absence of metabolic syndrome
Presumed type 2 diabetes diagnosed before 35 years old
Figure 4. Proposed diagnostic approach for differentiating transcription factor (HNF) monogenic diabetes from type 2 diabetes (T2D) (2,12,16,71,72,77,79,80,89,95,97).
C.-H. Lachance / Can J Diabetes 40 (2016) 368–375 373
The second patient demonstrated a classic presentation of GCK-
MODY in pregnancy (MODY probability calculator >75%). She tested
positive for the C.676G>A p.V226Mmutation. Treatment should not
be initiated during pregnancy until the results of the ﬁrst fetal ultra-
sound are obtained. In patients with this form of MODY who are
not pregnant, lifestyle interventions alone are suﬃcient and the prog-
noses are excellent. The fact that the patients’ babies were
macrosomic suggests that they did not inherit the glucokinasemuta-
tion, although testingwith fasting glucose and A1C levels will provide
better answers to the question.
The third patient tested positive for autosomal recessive com-
pound heterozygousmutations of the glucokinase gene during next-
generation sequencing, contrary to statistical predictions of a
sulfonylurea-sensitive gene. This patient carries 2 different muta-
tions, so glucose values are regulated even higher than in MODY 2,
and she has complications associated with hyperglycemia. Treat-
ment is indicated but remains diﬃcult despite multiple attempts.
Her mother, father, sister and daughter have glycemic proﬁles com-
patible with GCK-MODY.
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